Capital Increase in Genmab as a Result of Employee Warrant Exercise


Company Announcement

Copenhagen, Denmark; November 12, 2014 – Genmab A/S (OMX: GEN) will increase its share capital by 146,148 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

  • 400 shares at DKK 26.75,
  • 3,075 shares at DKK 31.75,
  • 2,250 shares at DKK 40.41,
  • 500 shares at DKK 46.74,
  • 5,625 shares at DKK 55.85,
  • 2,375 shares at DKK 67.50,
  • 1,125 shares at DKK 79.25,
  • 925 shares at DKK 80.55,
  • 4,500 shares at DKK 97,
  • 9,175 shares at DKK 101,
  • 47,750 shares at DKK 114,
  • 1,812 shares at DKK 116,
  • 2,000 shares at DKK 129.75,
  • 1,700 shares at DKK 130,
  • 39,062 shares at DKK 173,
  • 4,062 shares at DKK 184,
  • 5,062 shares at DKK 210.50,
  • 14,000 shares at DKK 224, and
  • 750 shares at DKK 234.

Proceeds to the company are approx. DKK 20.2 million. The increase corresponds to approx. 0.3 % of the company's share capital.

The increase includes the exercise of 45,000 warrants by President & CEO Jan van de Winkel, PhD and will take Jan van de Winkel’s personal holding of shares in Genmab A/S from 545,000 to 590,000 shares.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2014. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. Genmab A/S' current share capital amounts to DKK 56,821,271 and will after the capital increase be DKK 56,967,419. The capital increase is expected to be finalized shortly.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in late stage clinical development for multiple myeloma. Additionally Genmab has a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody™ and UniBody®. Arzerra® is a registered trademark of the GSK group of companies.

Company Announcement no. 54
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark


Attachments

54_warrant_exercise__121114_uk.pdf